Vol. 17/No. 14 | OncologyLive

Ribas Builds Foundation for Immunotherapy Success

July 07, 2016

Antoni Ribas, MD, PhD, whose work has helped guide and define the growing array of anticancer immunotherapy drugs, was honored in the Melanoma category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

BRAF Emerges as Exploitable Target in NSCLC

July 06, 2016

The types of BRAF mutations in non-small cell lung cancer may differ from those observed in melanoma, and a greater understanding of these nuances and their sensitivity to currently available drugs is a central focus of ongoing research.

Capmatinib Trial Targets New Molecular Subsets of Patients in NSCLC

July 04, 2016

An ongoing phase II, four-cohort trial involving capmatinib (INC280), an oral MET inhibitor, will determine the clinical activity of the agent in pretreated patients with advanced non-small cell lung cancer who have undergone one or two lines of therapy.

Zebrafish Are Making Waves as Cancer Models

June 30, 2016

The field of cancer biology is entering a postgenomic era in which most types of human cancer will have been extensively sequenced through efforts such as The Cancer Genome Atlas and the International Cancer Genome Consortium.